German Society of Neurology Guidelines for the Diagnosis and Treatment of Cognitive Impairment and Affective Disorders in People with Parkinson's Disease: New Spotlights on Diagnostic Procedures and Non-pharmacological Interventions

Overview

Journal J Neurol

Specialty Neurology

Date 2024 Aug 9

PMID 39120709

Authors

Elke Kalbe

Ann-Kristin Folkerts

Karsten Witt

Carsten Buhmann

Inga Liepelt-Scarfone

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson's disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on "Parkinson's disease" from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders.

Methods: The recommendations were based on literature reviews, other relevant guidelines, and expert opinions.

Results: Measurements to assess cognitive and affective states were reviewed for psychometric properties, use in routine clinical practice, and availability in German. To improve mild cognitive impairment, cognitive training and physical aerobic training are recommended. To treat Parkinson's disease (PD)-related dementia, cognitive stimulation (as a non-pharmacological intervention) and acetylcholinesterase inhibitors (AChEIs, i.e., rivastigmine) are recommended. Cognitive behavioral therapy is recommended to treat depression, anxiety, and fear of progression. Physical interventions are recommended to treat depression, fatigue, and apathy. Optimized dopaminergic treatment is the first-line pharmacological strategy recommended to manage depression, apathy, anhedonia, fatigue, and mood swings. Major depression can be additionally treated using venlafaxine or desipramine, while moderate depression can be treated pharmacologically according to its clinical phenotype (psychomotor retardation or agitation) and comorbidities (e.g., sleep disturbances, pain). Venlafaxine and nortriptyline can be used to treat anhedonia, while citalopram can be used for anxiety.

Conclusions: In addition to the updated pharmacological treatment options, new insights into recommendations for standardized diagnostics and non-pharmacological interventions were provided for the German health care system. However, more studies are needed to explore the full potential of non-pharmacological interventions to treat and prevent cognitive impairment and affective disorders.

Citing Articles

Impulse control disorders in Parkinson's disease: What's new?.

Marques A, Lewis S J Neurol. 2025; 272(2):138.

PMID: 39812828 DOI: 10.1007/s00415-024-12865-5.

Development and validation of a risk prediction model for cognitive impairment in breast cancer patients.

Zhang X, Lu J, Ding Z, Qiao Y, Li X, Zhong G BMC Psychiatry. 2024; 24(1):809.

PMID: 39548422 PMC: 11566113. DOI: 10.1186/s12888-024-06278-x.

Behavioral disorders in Parkinson disease: current view.

Jellinger K J Neural Transm (Vienna). 2024; 132(2):169-201.

PMID: 39453553 DOI: 10.1007/s00702-024-02846-3.

References

Richard I, McDermott M, Kurlan R, Lyness J, Como P, Pearson N . A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012; 78(16):1229-36. PMC: 3324323. DOI: 10.1212/WNL.0b013e3182516244. View

Macias-Garcia P, Rashid-Lopez R, Cruz-Gomez A, Lozano-Soto E, Sanmartino F, Espinosa-Rosso R . Neuropsychiatric Symptoms in Clinically Defined Parkinson's Disease: An Updated Review of Literature. Behav Neurol. 2022; 2022:1213393. PMC: 9110237. DOI: 10.1155/2022/1213393. View

Aarsland D, Batzu L, Halliday G, Geurtsen G, Ballard C, Chaudhuri K . Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021; 7(1):47. DOI: 10.1038/s41572-021-00280-3. View

Duncan G, Khoo T, Yarnall A, OBrien J, Coleman S, Brooks D . Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord. 2013; 29(2):195-202. DOI: 10.1002/mds.25664. View

Goodarzi Z, Mele B, Guo S, Hanson H, Jette N, Patten S . Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. BMC Neurol. 2016; 16(1):244. PMC: 5124305. DOI: 10.1186/s12883-016-0754-5. View

Aarsland D, Creese B, Politis M, Chaudhuri K, Ffytche D, Weintraub D . Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017; 13(4):217-231. PMC: 5643027. DOI: 10.1038/nrneurol.2017.27. View

Hely M, Reid W, Adena M, Halliday G, Morris J . The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008; 23(6):837-44. DOI: 10.1002/mds.21956. View

Bjornestad A, Pedersen K, Tysnes O, Alves G . Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. Parkinsonism Relat Disord. 2017; 42:28-33. DOI: 10.1016/j.parkreldis.2017.05.025. View

den Brok M, van Dalen J, van Gool W, Moll van Charante E, de Bie R, Richard E . Apathy in Parkinson's disease: A systematic review and meta-analysis. Mov Disord. 2015; 30(6):759-69. DOI: 10.1002/mds.26208. View

Svenningsson P, Westman E, Ballard C, Aarsland D . Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012; 11(8):697-707. DOI: 10.1016/S1474-4422(12)70152-7. View

Metta V, Logishetty K, Martinez-Martin P, Gage H, Schartau P, Kaluarachchi T . The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. Parkinsons Dis. 2011; 2011:125271. PMC: 3236421. DOI: 10.4061/2011/125271. View

Saredakis D, Collins-Praino L, Gutteridge D, Stephan B, Keage H . Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2019; 65:20-31. DOI: 10.1016/j.parkreldis.2019.04.020. View

10.

Telenius E, Engedal K, Bergland A . Effect of a high-intensity exercise program on physical function and mental health in nursing home residents with dementia: an assessor blinded randomized controlled trial. PLoS One. 2015; 10(5):e0126102. PMC: 4431827. DOI: 10.1371/journal.pone.0126102. View

10.

Lerche S, Wurster I, Roben B, Machetanz G, Zimmermann M, Bernhard F . Parkinson's disease: evolution of cognitive impairment and CSF Aβ profiles in a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2018; 90(2):165-170. DOI: 10.1136/jnnp-2018-318956. View

11.

Litvan I, Goldman J, Troster A, Schmand B, Weintraub D, Petersen R . Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012; 27(3):349-56. PMC: 3641655. DOI: 10.1002/mds.24893. View

12.

Dubois B, Burn D, Goetz C, Aarsland D, Brown R, Broe G . Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007; 22(16):2314-24. DOI: 10.1002/mds.21844. View

13.

Litvan I, Aarsland D, Adler C, Goldman J, Kulisevsky J, Mollenhauer B . MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011; 26(10):1814-24. PMC: 3181006. DOI: 10.1002/mds.23823. View

14.

Gibb W, Lees A . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51(6):745-52. PMC: 1033142. DOI: 10.1136/jnnp.51.6.745. View

15.

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

16.

Skorvanek M, Goldman J, Jahanshahi M, Marras C, Rektorova I, Schmand B . Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2017; 33(2):208-218. DOI: 10.1002/mds.27233. View